Table 1. Baseline characteristics of TB/HIV co-infected patients included in the study in Town 2 clinic from June 2008 to May 2009.
| Service integration | |||||
| All | Before | After | p-value | ||
| Total enrolled | 188 | 100 | 88 | ||
| Sex; n (%) | Female | 95 (50.5) | 50 (50.0) | 45 (51.1) | 0.876 |
| Male | 93 (49.5) | 50 (50.0) | 43 (48.9) | ||
| Age (years), median (IQR) | 35 (29–40) | 35.5 (28–41.5) | 34 (30–40) | 0.820 | |
| CD4 count; (cells/µl), median (IQR) | 87 (37–163) | 87.5 (50–169) | 83.5 (31.5–157.5) | 0.381 | |
| TB treatment category; n (%) | New | 136 (73.1) | 72 (72.7) | 64 (73.6) | 0.898 |
| Re-treatment | 50 (26.9) | 27 (27.3) | 23 (26.4) | ||
| TB initiation*; n (%). In clinic | 115 (61.2) | 59 (59.0) | 56 (63.6) | 0.775 | |
| Outside clinic | 1–14 days | 41 (21.8) | 22 (22.0) | 19 (21.6) | |
| 15–60 days | 25 (13.3) | 14 (14.0) | 11 (12.5) | ||
| ≥61 days | 7 (3.7) | 5 (5.0) | 2 (2.3) | ||
| TB classification; n (%) | Pulmonary | 121 (64.4) | 70 (70.0) | 51 (58.0) | 0.051 |
| Extrapulmonary | 57 (30.3) | 23 (23.0) | 34 (38.6) | ||
| Both | 10 (5.3) | 7 (7.0) | 3 (3.4) | ||
TB Rx, TB treatment; IQR, interquartile range. *In clinic: TB treatment initiated in study clinic; outside clinic: number of days of TB treatment received in referral clinic before TB registration and treatment continuation in the study clinic.